US EditionPublished • loading... • Updated
Valneva Reports Final Results From Phase II Lyme Disease Vaccine Trial
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Valneva reports final results from Phase II Lyme disease vaccine trial
Valneva has reported final safety and immunogenicity findings from the randomised Phase II trial, VLA15-221, assessing the Lyme disease vaccine candidate VLA15.The post Valneva reports final results from Phase II Lyme disease vaccine trial appeared first on Clinical Trials Arena.
https://www.tradingsat.com/valneva-FR0004056851/actualites/valneva-de-new-results-clinical-positive-on-son-vaccin-against-the-disease-lyme-portent-valneva-en-bourse-1151397.html
Biotech unveiled the final results of the Phase 2 study on this highly anticipated treatment by investors.
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
